# EDGAR Filing Document

**Accession Number:** 0000949858
**File Stem:** 0001193125-26-121817
**Filing Date:** 2026-3
**Character Count:** 27066
**Document Hash:** 99d42b004ea91748d7ad8f62566b2412
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-121817.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001193125-26-121817

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**EFFECTIVENESS DATE**: 20260324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACHIEVE LIFE SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000949858
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954343413
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294565
- **FILM NUMBER:** 26786332

**BUSINESS ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021
- **BUSINESS PHONE:** 425-686-1500

**MAIL ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ONCOGENEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20080821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SONUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19950825

**As filed with the Securities and Exchange Commission on March 24, 2026**

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER THE*** 

***SECURITIES ACT OF 1933*** 

------

**ACHIEVE LIFE SCIENCES, INC.** 

**(Exact name of Registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **95-4343413** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**22722 29th Drive SE, Suite 100**<br>**Bothell, WA** | &nbsp;&nbsp;**98021** |
| &nbsp;&nbsp;**1040 West Georgia, Suite 1030**<br>**Vancouver, BC, Canada** | &nbsp;&nbsp;**V6E 4H1** |
| &nbsp;&nbsp;**(Address of principal executive offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**2018 Equity Incentive Plan** 

**2017 Employee Stock Purchase Plan**

**(Full title of the plan)** 

**Richard Stewart**

**Chief Executive Officer** 

**22722 29th Drive SE, Suite 100**

**Bothell, WA 98021**

**(Name and address of agent for service)** 

**(604) 210-2217** 

**(Telephone number, including area code, or agent for service)**

***Please send copies of all communications to:*** 

**Alan Smith, Esq.** 

**Amanda Rose, Esq.** 

**Chelsea Anderson, Esq.**

**Fenwick & West LLP** 

------

**401 Union Street, 5th Floor**

**Seattle, WA 98101**

**(206) 389-4510** 

------

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**INTRODUCTORY NOTE**

**REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E**

Achieve Life Sciences, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") to register (a) 2,661,699 additional shares of common stock under the Registrant's 2018 Equity Incentive Plan ("***EIP***"), pursuant to the provisions of the EIP providing for an automatic increase in the number of shares reserved for issuance under the EIP on January 1, 2026 and (b) 532,339 additional shares of common stock under the Registrant's 2017 Employee Stock Purchase Plan ("***ESPP***"), pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares reserved for issuance under the ESPP on January 1, 2026. This Registration Statement hereby incorporates by reference the contents of the Registrant's previous registration statements on Form S-8 filed with the Commission on November 7, 2018 (Registration No. [<u>333-22853</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459018028096/achv-s8.htm)), May 15, 2019 (Registration No. [<u>333-231520</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459019019453/achv-s8.htm)), January 24, 2020 (Registration No. [<u>333-236059</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459020001895/achv-s8.htm)), March 11, 2021 (Registration No. [<u>333-254156</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459021012555/achv-s8.htm)), March 10, 2022 (Registration No. [<u>333-263421</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459022009644/achv-s8.htm)), March 16, 2023 (Registration No. [<u>333-270625</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459023003819/achv-s8.htm)), March 28, 2024 (Registration No. [<u>333-278335</u>](https://www.sec.gov/Archives/edgar/data/949858/000095017024038136/achv_march_2024_form_s-8.htm)) and January 10, 2025 Registration (No. [<u>333-284208</u>](https://www.sec.gov/Archives/edgar/data/949858/000095017025004143/jan_10_2025_s-8.htm)) to the extent not superseded hereby.

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

---

| | |
|:---|:---|
| **Item 3.** | **Incorporation of Documents by Reference.**  |

---

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "***Exchange Act***") are incorporated herein by reference:

(a) the Registrant's [<u>Annual Report on Form 10-K</u>](https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm) for the fiscal year ended December 31, 2025, filed with the Commission March 24, 2026 pursuant to Section 13 of the Exchange Act;

(b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant's Annual Report referred to in (a) above; and

(c) the description of the Registrant's common stock contained in the Company's Registration Statement on Form 8-A filed with the Commission on September 27, 1995 (paper filing), pursuant to Section 12(b) of the Exchange Act, including any other amendments or reports filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.**  |

---

The following exhibits are filed herewith:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit<br>Number** |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed<br>Herewith** |
| **Exhibit<br>Number** | **Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |  |
| 4.1 | [<u>Third Amended and Restated Certificate of Incorporation</u>](https://www.sec.gov/Archives/edgar/data/0000949858/000119312523164423/d503566dex31.htm) | 8-K | 033-80623 | 3.1 | 6/9/2023 |  |
| 4.2 | [<u>Sixth Amended and Restated Bylaws</u>](https://www.sec.gov/Archives/edgar/data/949858/000119312517003020/d310875dex31.htm) | 8-K | 033-80623 | 3.1 | 1/5/2017 |  |
| 4.3 | [<u>Amendment (Virtual Meeting) to Sixth Amended and Restated Bylaws</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459018028073/achv-ex31_529.htm) | 10-Q | 033-80623 | 3.1 | 11/7/2018 |  |
| 4.4 | [<u>Form of Registrant's Common Stock certificate</u>](https://www.sec.gov/Archives/edgar/data/949858/000091228208001616/ex4_1.htm) | 10-Q | 000-21243 | 4.1 | 11/10/2008 |  |
| 5.1 | [<u>Opinion of Fenwick & West LLP</u>](achv-ex5_1.htm) |  |  |  |  | X |
| 23.1 | [<u>Consent of Fenwick & West LLP (contained in Exhibit 5.1)</u>](achv-ex5_1.htm) |  |  |  |  | X |
| 23.2 | [<u>Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</u>](achv-ex23_2.htm) |  |  |  |  | X |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| 24.1 | [<u>Power of Attorney (included on the signature page to this Registration Statement)</u>](#power_attorney) |  |  |  |  | X |
| 99.1 | [<u>2018 Equity Incentive Plan and forms of award agreements thereunder</u>](https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-ex108_499.htm) | 10-K | 033-80623 | 10.8 | 3/16/2023 |  |
| 99.2 | [<u>2017 Employee Stock Purchase Plan</u>](https://www.sec.gov/Archives/edgar/data/949858/000119312517290461/d435757ddef14a.htm#toc435757_17) | DEF 14A | 033-80623 | Appendix B | 9/21/2017 |  |
| 107.1 | [<u>Filing Fee Table</u>](achv_exfilingfees.htm) |  |  |  |  | X |

---

**Item 9. Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.The undersigned Registrant hereby undertakes:

1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; <u>provided</u>, <u>however</u>, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities

------

(other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bothell, Washington, on this 24th day of March, 2026.

---

| | |
|:---|:---|
| **ACHIEVE LIFE SCIENCES, INC.** | **ACHIEVE LIFE SCIENCES, INC.** |
| By: | /s/ Mark Oki |
|  | Mark Oki<br>*Chief Financial Officer* |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints Richard Stewart, Mark Oki and Erik Atkisson and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Richard Stewart<br>Richard Stewart | &nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer and Director<br>(Principal Executive Officer) | March 24, 2026 |
| /s/ Mark Oki<br>Mark Oki | &nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer<br>(Principal Financial Officer) | March 24, 2026 |
| /s/ Jerry Wan<br>Jerry Wan | &nbsp;&nbsp;&nbsp;&nbsp;Vice President, Finance<br>(Principal Accounting Officer) | March 24, 2026 |
| /s/ Thomas B. King<br>Thomas B. King | Chairman of the Board of Directors | March 24, 2026 |
| /s/ Stuart Duty<br>Stuart Duty | &nbsp;&nbsp;&nbsp;&nbsp;Director | March 24, 2026 |
| /s/ Bridget Martell<br>Bridget Martell | &nbsp;&nbsp;&nbsp;&nbsp;Director | March 24, 2026 |
| /s/ Nancy Phelan<br>Nancy Phelan | &nbsp;&nbsp;&nbsp;&nbsp;Director | March 24, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Thomas Sellig<br>Thomas Sellig | &nbsp;&nbsp;&nbsp;&nbsp;Director | March 24, 2026 |
| /s/ Kristen B. Slaoui, Ph.D.<br>Kristen B. Slaoui, Ph.D. | &nbsp;&nbsp;&nbsp;&nbsp;Director | March 24, 2026 |

---

------

## Exhibit 5.1

**Exhibit 5.1**

![img223336490_0.jpg](img223336490_0.jpg)

March 24, 2026

Achieve Life Sciences, Inc.

22722 29th Drive SE, Suite 100

Bothell, WA 98021

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

As counsel to Achieve Life Sciences, Inc., a Delaware corporation (the "Company"), we have examined the Registration Statement on Form S-8 (the "Registration Statement") to be filed by the Company with the Securities and Exchange Commission (the "Commission") on or about March 24, 2026 in connection with the registration under the Securities Act of 1933, as amended (the "Securities Act"), of an aggregate of 3,194,038 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), that consists of (a) 2,661,699 shares of Common Stock that are subject to issuance by the Company upon the exercise or settlement of awards to be granted under the Company's 2018 Equity Incentive Plan, as amended (the "2018 Plan"), and (b) 532,339 shares of Common Stock subject to purchase rights to acquire such shares under the Company's 2017 Employee Stock Purchase Plan (the "Purchase Plan," and together with the 2018 Plan, the "Plans").

As to matters of fact relevant to the opinions rendered herein, we have examined such documents, certificates and other instruments which we have deemed necessary or advisable, including a certificate addressed to us and dated the date hereof executed by the Company. We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties or to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of the Company or the rendering of the opinion set forth below. We have not considered parol evidence in connection with any of the agreements or instruments reviewed by us in connection with this letter.

In our examination of documents for purposes of this letter, we have assumed, and express no opinion as to, the genuineness and authenticity of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, that each document is what it purports to be, the conformity to originals of all documents submitted to us as copies or facsimile copies, the absence of any termination, modification or waiver of or amendment to any document reviewed by us (other than as has been disclosed to us), the legal competence or capacity of all persons or entities (other than the Company) executing the same and (other than the Company) the due authorization, execution and delivery of all documents by each party thereto. We have also assumed the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System ("EDGAR"), except for required EDGAR formatting changes, to physical copies submitted for our examination.

The opinions in this letter are limited to the existing General Corporation Law of the State of Delaware now in effect. We express no opinion with respect to any other laws.

------

Based upon, and subject to, the foregoing, it is our opinion that the Shares, when issued and sold by the Company in accordance with the terms (including, without limitation, payment and authorization provisions) of the applicable Plan and the applicable form of award agreement thereunder, against the Company's receipt of payment therefor (in an amount and type of consideration not less than the par value per Share), and duly registered on the books of the transfer agent and registrar for the Shares in the name or on behalf of the holders thereof, will be validly issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the prospectuses constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

This opinion is intended solely for your use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.

Very truly yours,

*/s/ Fenwick & West LLP*

Fenwick & West LLP

------

## Exhibit 23.2

## EXHIBIT 23.2

## <u>Consent of Independent Registered Public Accounting Firm</u> 
We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 relating to the 2018 Equity Incentive Plan and 2017 Employee Stock Purchase Plan of Achieve Life Sciences, Inc. (the Company) of our report dated March 24, 2026 relating to the consolidated financial statements, which appears in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/PricewaterhouseCoopers LLP

**Chartered Professional Accountants**<br>Vancouver, Canada

March, 24, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**EXHIBIT 107.1**

---

| |
|:---|
| **Calculation of** Filing Fee **Tables** |
| **Form** S-8 **Registration Statement** |
| Achieve Life Sciences, Inc.  |

---

**Table 1: Newly Registered Securities**<br>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security Type | **Security Class Title**  | **Fee Calculation Rule** | **Amount Registered** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| 1  | Equity | Common stock, par value $0.001 per share  | Other | 2661699 | $4.05 | $10779880.95 | 0.0001381 | $1488.71 |
| 2 | Equity | Common stock, par value $0.001 per share | Other | 532339 | $3.44 | $1831246.16 | 0.0001381 | $252.90 |
|  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $12611127.11 |  | $1741.61 |
|  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  |  |
|  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1741.61 |

---

<br>**Offering Note**<br>

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp;Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock"), that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Achieve Life Sciences, Inc.'s (the "Registrant") Common Stock.  |
| 1 | &nbsp;&nbsp;&nbsp; <br>&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents additional shares of Common Stock to be registered and available for grant under the Registrant's 2018 Equity Incentive Plan (the "EIP") resulting from the annual automatic increase in shares available for issuance under the EIP pursuant to the provision of the EIP providing for an annual automatic increase in the number of shares reserved for issuance under the EIP. <br>&nbsp;&nbsp;&nbsp;&nbsp;(2) Estimated pursuant to Rules 457(c) and 457(h) under the Securities Act, solely for the purposes of calculating the registration fee and based on the average of the high and low prices of Common Stock as reported on The Nasdaq Stock Market LLC ("Nasdaq") on March 20, 2026, which date is within five business days prior to the filing of this Registration Statement.<br>|
| 2 | &nbsp;&nbsp;&nbsp; <br>&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents additional shares of Common Stock to be registered and available for grant under the Registrant's 2017 Employee Stock Purchase Plan (the "ESPP") resulting from the annual automatic increase in shares available for issuance under the ESPP pursuant to the provision of the ESPP providing for an annual automatic increase in the number of shares reserved for issuance under the ESPP.<br>&nbsp;&nbsp;&nbsp;&nbsp;(2) Estimated pursuant to Rules 457(c) and 457(h) under the Securities Act, solely for the purposes of calculating the registration fee and based on the average of the high and low prices of Common Stock as reported on Nasdaq on March 20, 2026, which date is within five business days prior to the filing of this Registration Statement, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the ESPP.<br>|

---

------